Urethral stricture

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Hospital, Urination, Friction, Growth, Prevalence, Risk, Trauma, Research, Dilator, Cook Group, Urethral stricture, Urethra, MED, Medical imaging

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Retrieved on: 
Wednesday, October 18, 2023
Research, Hospitals, Health Technology, Stem Cells, Biotechnology, Training, University, Health, Science, Education, Cellular senescence, Regenerative medicine, PD, Cell biology, Urethral stricture, IDC, Tissue engineering, FCQ, Sri Ramachandra Institute of Higher Education and Research, Cell, GSZ, Multimedia, Tree (graph theory), Code, Tissue, German Society for Stem Cell Research, Genome, Kasturba Medical College, Disease, Buccal, University of Cologne, Duchenne muscular dystrophy, XVIII, Radboud University Medical Center, Hospital, Chondrocyte, McEwen Centre for Regenerative Medicine, Stem cell, Multiple sclerosis, NCRM, Thai-Nichi Institute of Technology, Safety, DMD, Autism spectrum, Synthetic biology, ASD, Edogawa, MS, B cell, Pharmaceutical industry, RM

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize.
  • The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch.
  • NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs.

Urotronic Announces Presentation of Data from Two Clinical Trials Evaluating Optilume® BPH System's Effectiveness and Durability

Retrieved on: 
Monday, May 1, 2023
Male, Icahn School of Medicine at Mount Sinai, BPH, Food, AUA, Urethral stricture, CE marking, LUTS, International Prostate Symptom Score, Paclitaxel, Quality of life, American Urological Association, PINNACLE, Food and Drug Administration, Mount Sinai, Sale, MIST, U.S. FDA, High, Lower urinary tract symptoms, Patient, Randomness, Trial of the century, FDA, Urology, IPSS, Medical imaging, Medical device, Pharmaceutical industry, Spirometry

MINNEAPOLIS, May 1, 2023 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its drug-coated balloon technology for use in interventional urology, today announced the presentation of positive data from two clinical trials evaluating the Optilume® BPH System's effectiveness and durability in treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Four-year and 12-month data from the EVEREST and PINNACLE clinical trials were presented by Dr. Steven A. Kaplan, professor of urology at the Icahn School of Medicine at Mount Sinai in New York and the principal investigator of the two studies, during the American Urological Association's (AUA) Annual Meeting in Chicago.

Key Points: 
  • "The positive data from the PINNACLE and EVEREST trials – including the highest reported Qmax in BPH MIST trials to date – demonstrates clear and compelling sustained clinical outcomes through four years post-treatment," said Dr. Kaplan.
  • "Optilume BPH is not your grandfather's BPH balloon – it's the next generation of minimally invasive technology, creating a new drug device space among BPH therapies."
  • Mechanical dilation with Optilume BPH achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
  • The highest average peak urinary flow rate (Qmax) at 12 months reported in randomized MIST trials for BPH.

American Urological Association Releases Urethral Strictures Disease Guideline Update

Retrieved on: 
Tuesday, April 25, 2023
Contracture, University, Urethral stricture, Guideline, Stenosis, AUA, University of Washington Department of Global Health, American Urological Association, Woman, Literature, Urethroplasty, MD, Urology, Wessel H. Smitter, Diagnosis, Research, Female, Disease, Medical device, Dentistry

BALTIMORE, April 25, 2023 /PRNewswire/ -- Today, the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and management of urethral stricture disease.

Key Points: 
  • BALTIMORE, April 25, 2023 /PRNewswire/ -- Today, the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and management of urethral stricture disease.
  • This guideline has 33 recommendations and serves as a useful reference on the effective evidence-based diagnosis and management of urethral stricture disease.
  • The original guideline was published in 2016 to identify literature relevant to the diagnosis and treatment of urethral stricture in men.
  • A summary of the Guideline also appears at:
    Wessells H, Morey A, Alex Vanni, Rahimi L, Souter L. Urethral stricture disease guideline amendment (2023).

Laborie's Optilume® Issued Category 1 CPT Code by American Medical Association

Retrieved on: 
Monday, November 7, 2022
American Medical Association, Hospital, Gynaecology, Investor AB, Wallenberg, CEO, Adoption, Physician, AMA, Urethral stricture, CPT, Technology, Indian Medical Association, Patient, Obstetrics, Pharmaceutical industry, Medical device, Urology, Gastroenterology

PORTSMOUTH, N.H., Nov. 7, 2022 /PRNewswire/ -- Laborie Medical Technologies Corp (Laborie), a specialist medical technology company, announced today that the American Medical Association (AMA) has issued the new Category 1 Current Procedural Terminology (CPT®) code 5X000 to report cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery via coated balloon. The new code is applicable to services that physicians perform with the company's Optilume Urethral Drug Coated Balloon, a first-of-its-kind technology for the treatment of patients with urethral stricture.

Key Points: 
  • The new code is applicable to services that physicians perform with the company's Optilume Urethral Drug Coated Balloon, a first-of-its-kind technology for the treatment of patients with urethral stricture.
  • The technology was developed in response to patient and physician dissatisfaction with current endoscopic solutions for urethral strictures.
  • It provides a durable, cost effective, minimally invasive treatment option for millions of patients suffering from these conditions globally.
  • Beginning January 1, 2024, providers will be able to report the new CPT code for Optilume.

LAMEA External Urine Management Products Market to Grow by 6.7% Annually Through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 7, 2022
Utilities, Energy, Online, Biofilm, Distribution, LaTeX, Urethral stricture, Clifton Springs Hospital & Clinic, Water, Prostate, CAGR, Hospital, Country, Growth, Catheter, Synthetic rubber, Tiemann

The "LAMEA External Urine Management Products Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Offline and Online), By Product, By End- use (Hospitals, Clinics, Home Care Settings), By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LAMEA External Urine Management Products Market Size, Share & Industry Trends Analysis Report By Distribution Channel (Offline and Online), By Product, By End- use (Hospitals, Clinics, Home Care Settings), By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Brazil market dominated the LAMEA External Urine Management Products Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $12.9 million by 2028.
  • The Argentina market is experiencing a CAGR of 7.3% during (2022 - 2028).
  • Additionally, The UAE market is expected to display a CAGR of 6.4% during (2022 - 2028).

UCI Urology Celebrates Historic Dual Chair Investiture

Retrieved on: 
Friday, March 25, 2022
UCI, Health, UCI School of Biological Sciences, David Geffen School of Medicine at UCLA, Engineering, Leadership, Telekom Innovation Laboratories, Multimedia, Education, University of California, Research, Faculty, School, Pathology, Urethral stricture, View, Peyronie's disease, Curiosity, Income, Department, University, Department of Urology, University of Virginia, Creativity, Medical device, Hospital, Online shopping, Medicine

NEWPORT BEACH, Calif., March 25, 2022 /PRNewswire/ --On March 15, 2022, UCI Urology celebrated a historic dual chair investiture honoring Dr. Jaime Landman and Dr. Joshua Mauney.

Key Points: 
  • NEWPORT BEACH, Calif., March 25, 2022 /PRNewswire/ --On March 15, 2022, UCI Urology celebrated a historic dual chair investiture honoring Dr. Jaime Landman and Dr. Joshua Mauney.
  • Endowed Chair in Urologic Surgical Oncology and Dr. Joshua Mauney received the Jerry D. Choate Presidential Chair in Urology Tissue Engineering.
  • This celebration honored the installment of the fifth and sixth Endowed Chairs to UCI Health Department of Urology.
  • "The endowed chair has provided truly transformative funding for our laboratory which is allowing us to create key advancements in urologic tissue engineering.

The OPTRACT Method: Efficient Human Donor Cornea Transportation Feat & Futuristic Cell Repository in Zero-gravity for Space-age, Anti-aging Research; Strategy by Japanese Scientists.

Retrieved on: 
Thursday, March 3, 2022
Science, Biotechnology, Research, Optical, General Health, Health, Medical Devices, Other Health, Chondrocyte, Ageing, Transplant, Cellular senescence, Bone marrow, MACI, Phenotype, B cell, Patient, Regenerative medicine, Hospital, Research, Urethral stricture, Cell biology, Laboratory, Cornea, Solution, Culture, Nitric oxide, Multimedia, Cancer, Cartilage, Cryopreservation, Frailty, Cell, Maintenance, ACI, Male, GN, Cadaver, Transport, Planet, Tissue, Pharmaceutical industry, Wood-plastic composite, Vaccine

A much efficient human cadaver donor-corneal transportation method, developed by Japanese scientists, may increase the availability of donated eyes to millions of patients with corneal blindness, waiting for corneal transplantation restoring vision.

Key Points: 
  • A much efficient human cadaver donor-corneal transportation method, developed by Japanese scientists, may increase the availability of donated eyes to millions of patients with corneal blindness, waiting for corneal transplantation restoring vision.
  • The OPTRACT method, better preserving human buccal tissue and cartilage during transport between hospitals and laboratories, reverses cellular aging, beside being granted a Japanese patent for functional enhancement of immune cells under micro-gravity.
  • These accomplishments harbinger a futuristic strategy of evaluating the implications of inter-stellar environments on human cells aboard a space station without gravity, which if defies aging related damages, may yield solutions to frailty of aging, researchers opine.
  • The OPTRACT method based in vitro culture has yielded reversal of senescence of human chondrocytes in the lab, employing proprietary tissue engineering techniques.

FDA Approves Optilume® Urethral Drug Coated Balloon, a breakthrough treatment for urethral strictures

Retrieved on: 
Monday, December 13, 2021
Method, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Urethral stricture, Stenosis, Freedom, Patient, Trauma, Recurrence, Stricture, FDA, Urology, CEO, Paclitaxel, Treatment, Incidence, Urethra, Food, Infection, Medical device, IPSS

MINNEAPOLIS, Dec. 13, 2021 /PRNewswire/ -- Urotronic, Inc., a Minnesota based medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Optilume® Urethral Drug Coated Balloon for use in male urethral strictures. Optilume was granted CE mark approval for use in urethral strictures in 2020.

Key Points: 
  • Optilume was granted CE mark approval for use in urethral strictures in 2020.
  • Optilume is the treatment that breaks the cycle of recurrent urethral strictures."
  • MP56-07: Interim Results for the ROBUST III Trial Evaluating the Optilume Drug Coated Balloon for Anterior Urethral Strictures.
  • Heyns CF, Steenkamp JW, De Kock MLS, Whitaker P. Treatment of male urethral strictures: is repeated dilation or internal urethrotomy useful?